SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances higher full-year revenue guidance, attributed to stronger demand for Amtagvi and Proleukin, is driving the rally and is being viewed by traders as evidence of improving commercial momentum. The reaction is broadly bullish, with many also anticipating NSCLC data; short-squeeze and takeover talk remains speculative.

Carnival Corp. Ltd. engages in the operation of cruise ships. It operates through the following business segments: North America Cruise Operations, Europe Cruise Operations, Cruise Support, and Tour and Others. The North America Cruise Operations segment includes the Carnival Cruise Line, Holland America Line, Princess Cruises, and Seabourn. The Europe Cruise Operations segment consists of AIDA, Costa, Cunard, and P&O Cruises (UK). The Cruise Support segment represents port destinations and private islands for the benefit of its cruise brands. The Tour and Other segment operates hotel and transportation operations of Holland America Princess Alaska Tours. The company was founded in 1972 and is headquartered in Miami, FL.

Carnival Corporation Ltd.

Carnival Corp

Carnivals quarterly results topped expectations, while full-year adjusted EPS guidance edged higher and management cited record booking occupancy and pricing for 2027, driving a sharp rally. Bulls celebrated the beat and pressured shorts, while some traders pointed to weaker-than-expected fourth-quarter EPS guidance and elevated fuel costs as risks.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas selection for a U.S. Army program to develop next-generation 10 kV silicon-carbide semiconductors has drawn attention as a technology and domestic-manufacturing validation. Traders are bullish on the potential defense and infrastructure applications, while others caution that the prototype awards financial terms are undisclosed and may not translate into near-term revenue, fueling debate over whether the initial rally can hold.

AST SpaceMobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an intellectual property and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobiles new change-of-control severance policy has fueled speculation about a possible buyout or strategic deal, though traders disagree on whether it signals anything beyond routine governance and the filing does not confirm a transaction. The debate is sharpened by frustration over the lack of a shipment or launch date for BlueBirds 1416, alongside bullish buying and bearish concerns about execution and volatile trading.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

BEs rebound is being tied to easing concerns over Oracles force majeure notice for Project Jupiter: traders say Oracles fuel-cell commitment remains intact, though some remain wary of project delays and permitting risks. Bulls also cite Blooms Fremont manufacturing expansion as a sign of strong demand.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

AstraZenecas strategic investment and clinical collaboration around Summits cancer drug ivonescimab are driving attention, with traders viewing the deal as funding and validation for the biotech. Optimism about the partnership and possible short covering is tempered by reminders that it is not a buyout and that FDA approval remains uncertain.

Fair Isaac Corp. engages in the provision of decision management solutions. It operates through the Software and Scores segments. The Software segment includes pre-configured analytic and decision management solutions designed for a specific type of business need or process. The Scores segment focuses on business-to-business scoring solutions and services, business-to-consumer scoring solutions and services including myFICO solutions for consumers and associated professional services. The company was founded by Bill Fair and Earl Isaac in 1956 and is headquartered in San Jose, CA.

Fair Isaac Corp.

Fair, Isaac Corp.

FHFA changes to mortgage pricing that allow VantageScore alongside FICO are driving a sharp selloff, as traders weigh the threat to FICOs longstanding mortgage-scoring advantage and pricing power. The community is split between viewing the move as a serious competitive threat with further downside and treating the drop as an overreaction and buying opportunity.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure shares are under pressure after four-year AMT-130 data for Huntingtons disease showed less slowing on the primary measure than the stronger three-year results, with the four-year result not statistically significant. Traders debate whether the selloff is an overreaction because the BLA is based on the three-year data, while others question whether the longer-term results weaken the approval case.

Norwegian Cruise Line Holdings Ltd. engages in the provision of cruise travel services. It offers cruise experiences for travelers with itineraries in Europe, Asia, Australia, New Zealand, South America, Africa, Canada, Bermuda, Caribbean, Alaska and Hawaii. Its brands include Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises. The company was founded in 1966 and is headquartered in Miami, FL.

Norwegian Cruise Line Holdings Ltd

NCLH is drawing attention as cruise stocks attempt a rebound after a steep selloff, with traders focused on the Iran-related oil shock and its potential to raise fuel costs. Bulls point to oversold conditions and heavy short interest as possible support for a recovery, while bears remain concerned about fuel expenses, weaker yield expectations and the companys debt.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

The U.S. Air Force expanded DZYNEs contract for its ULTRA long-endurance reconnaissance drone, which traders view as validation of Ondas defense portfolio and potential relevance to future Reaper-replacement programs. Bullish posts cite the contract and short-squeeze potential, while skeptics point to dilution concerns and the stocks limited response to positive news.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$AIFF AI analysis, food for thought: 
 
At 1/10,000 Market Impact ($1.6M): Capturing just 0.01% of the global ADHD space nearly doubles Firefly&#39;s existing revenue base. 
 
At 1/1,000 Market Impact ($16M): Capturing 0.10% of the market represents an 8.9x increase over their current annual revenue.  
 
What This Looks Like in Real-World Adoption-&gt;To contextualize a 1/1,000 market impact ($16 million) for a diagnostic platform paired with a non-drug device: There are an estimated 7.1 million diagnosed children in the U.S. alone. If Firefly charges clinics a modest fee per scan (or takes a structural cut of the non-drug treatment workflow), they do not need millions of patients. If an integrated diagnostic-and-treatment cycle generates a combined value of just $500 per patient annually, they would only need to penetrate 32,000 patients globally to reach $16 million. That equates to less than 0.5% of the U.S. pediatric ADHD population alone, leaving the remaining 99.5% of the market untouched

StockTwits Web

Firefly Neuroscience Inc.

 AI analysis, food for thought: 
 
At 1/10,000 Market Impact ($1.6M): Capturing just 0.01% of the global ADHD space nearly doubles Firefly's existing revenue base. 
 
At 1/1,000 Market Impact ($16M): Capturing 0.10% of the market represents an 8.9x increase over their current annual revenue.  
 
What This Looks Like in Real-World Adoption->To contextualize a 1/1,000 market impact ($16 million) for a diagnostic platform paired with a non-drug device: There are an estimated 7.1 million diagnosed children in the U.S. alone. If Firefly charges clinics a modest fee per scan (or takes a structural cut of the non-drug treatment workflow), they do not need millions of patients. If an integrated diagnostic-and-treatment cycle generates a combined value of just $500 per patient annually, they would only need to penetrate 32,000 patients globally to reach $16 million. That equates to less than 0.5% of the U.S. pediatric ADHD population alone, leaving the remaining 99.5% of the market untouched

Einstein

@FLArnot FYI, that device only does $1M in revenue per year. And its old, its been around since 2019.

 FYI, that device only does $1M in revenue per year. And its old, its been around since 2019.

Ryker Jones

@Easteregg The original NeuroSigma was approved in 2019.  The second version was FDA approved in 2024 and became commercially available in July of 2026.  So yes, the original tech was around in 2019, but it was clunky and not well marketed.  The new version is 1/3 the size and has a high resolution screen, and just now getting to the market.

 The original NeuroSigma was approved in 2019.  The second version was FDA approved in 2024 and became commercially available in July of 2026.  So yes, the original tech was around in 2019, but it was clunky and not well marketed.  The new version is 1/3 the size and has a high resolution screen, and just now getting to the market.

@FLArnot I wonder why it took so long to become commercially available since it was approved in 2024. So it took about 2 years for the improved version to be sellable.

 I wonder why it took so long to become commercially available since it was approved in 2024. So it took about 2 years for the improved version to be sellable.